Exosomes are vesicle-type natural biological particles produced by cell secretion.
On October 14, 2021, Beijing time, researchers from the State Key Laboratory of Biochemical Engineering at the Institute of Process Engineering of the Chinese Academy of Sciences (hereinafter referred to as the Institute of Process Engineering) published their latest paper in Science Translational Medicine
Dr.
Screenshot of the paper webpage
Screenshot of the paper webpage Tumor immunotherapy can mobilize the body's own immune cells to recognize and kill tumors, and is a new strategy for tumor treatment with great potential
Inspired by the immune activation effect of immune cell exosomes and tumor cell homing phenomenon of tumor cell exosomes, the State Key Laboratory of Biochemical Engineering of the Institute of Process Engineering faces the actual needs of clinical applications, combined with more than ten years of granular formulation and vaccine delivery Based on the research experience of tumor immunity, a new strategy of lymph node-tumor dual-targeted exosomes for dual-effect synergistic tumor immunotherapy was proposed
Schematic diagram of the preparation of chimeric exosomes and their use in dual-effect synergistic tumor immunotherapy (photo courtesy of the research team)
Schematic diagram of the preparation of chimeric exosomes and their use in dual-effect synergistic tumor immunotherapy (photo courtesy of the research team) In the latest research, the research team selected macrophages with strong phagocytic ability to ingest tumor cell nuclei, and after in vitro immune domestication, immune-activated macrophage-tumor hybrid cells were formed
Through the above-mentioned innovative strategy of double-targeting in space and dual-effect synergy of mechanism, it is possible to ensure that effector T cells exert immune killing in the tumor to the greatest extent, and significantly improve the effect of immunotherapy
The research team further demonstrated on various animal tumor models of lymphoma, breast cancer, and melanoma that chimeric exosomes can significantly inhibit the progression of tumors in situ, metastatic tumors, and recurring tumors after surgery, and the effect is far superior to the current ones.
The in vivo mechanism of chimeric exosomes and their efficacy in orthotopic tumor models: (A) Chimeric exosomal lymph node-tumor dual-targeted in vivo fluorescence imaging; (B) Chimeric exosomes activate intra-lymph node immunity Immunofluorescence section of the response; (CE) Chimeric exosomes improve the immunosuppressive microenvironment within the tumor; (F) Growth curve and survival curve of mouse orthotopic tumors after different treatments (photo courtesy of the research team)
The in vivo mechanism of chimeric exosomes and their efficacy in orthotopic tumor models: (A) Chimeric exosomal lymph node-tumor dual-targeted in vivo fluorescence imaging; (B) Chimeric exosomes activate intra-lymph node immunity Immunofluorescence section of the response; (CE) Chimeric exosomes improve the immunosuppressive microenvironment within the tumor; (F) Growth curve and survival curve of mouse orthotopic tumors after different treatments (photo courtesy of the research team) According to the researchers, the above results are still pre-clinical studies, and the actual clinical efficacy still needs to be further verified
After six years of research, this work is another innovative formulation of the team with clinical transformation potential
This work has won the National Natural Science Foundation of China Key Project, National Natural Science Foundation of China Innovation Group Project, National Natural Science Foundation of China Joint Fund Project, Chinese Academy of Sciences Strategic Leading Science and Technology Special Project, National Key Research and Development Program Project, State Key Laboratory of Biochemical Engineering Open Fund and China Postdoctoral Fellow Fund support
Chinese Academy of Sciences Related paper information: https://doi.
https://doi.
org/ 10.
1126/scitranslmed.
abb6981 10.
1126/scitranslmed.
abb6981
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![9-[1,1'-biphenyl]-4-yl-3,3'-Bi-9H-carbazole](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
